Current and emerging treatment strategies for anal cancer

Current Oncology Reports

Volumn 12, Issue 3, 2010, Pages 168-174

  Meyer, Jeffrey ^a   Willett, Christopher ^b   Czito, Brian ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anal cancer; Chemotherapy; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; MITOMYCIN C; OXALIPLATIN;

ADJUVANT THERAPY; ANUS CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTENSITY MODULATED RADIATION THERAPY; LUNG TOXICITY; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STANDARD; TREATMENT PLANNING; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; RADIOTHERAPY;

EID: 77952243800     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0100-9     Document Type: Review

References (30)

1. AA Forastiere H Goepfert M Maor, et al. 2003 Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer New Engl J Med 349 2091 2098 10.1056/NEJMoa031317 1:CAS:528:DC%2BD3sXptlKiu7s%3D 14645636 (Pubitemid 37464533)
2. ND Nigro VK Vaitkevicius B Considine Jr 1977 Combined therapy for cancer of the anal canal: a follow-up report Dis Colon Rectum 20 677 678 10.1007/BF02586688 923397
3. BM Boman CG Moertel MJ O'Connell, et al. 1984 Carcinoma of the anal canal. A clinical and pathologic study of 188 cases Cancer 54 114 125 10.1002/1097-0142(19840701)54:1<114::AID-CNCR2820540124>3.0.CO;2-P 1:STN:280:DyaL2c3gsFanug%3D%3D 6326995 (Pubitemid 14117057)
4. ND Nigro VK Vaitkevicius B Considine Jr 1974 Combined therapy for cancer of the anal canal: a preliminary report Dis Colon Rectum 17 354 356 10.1007/BF02586980 1:STN:280:DyaE2c7ntFelsA%3D%3D 4830803
5. Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996, 348:1049-1054.
6. H Bartelink F Roelofsen F Eschwege, et al. 1997 Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups J Clin Oncol 15 2040 2049 1:CAS:528:DyaK2sXjsVCrt7k%3D 9164216 (Pubitemid 27209535)
7. M Flam M John T Pajak, et al. 1996 Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study J Clin Oncol 14 2527 2539 1:CAS:528:DyaK28XlvVGisr0%3D 8823332 (Pubitemid 26300120)
8. J Ajani K Winter L Gunderson, et al. 2008 Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. A randomized controlled trial JAMA 299 1914 1921 10.1001/jama.299.16.1914 1:CAS:528:DC%2BD1cXltFWgsLs%3D 18430910 (Pubitemid 351574921)
9. R James S Wan R Glynne-Jones, et al. 2009 A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [suppl; abstr LBA4009] J Clin Oncol 27 18s 10.1200/JCO.2009.22.4626
10. Conroy T, Ducreux M, Lemanski C, et al.: Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal carcinoma (LAAC): definitive analysis of the intergroup ACCORD 03 trial [abstract 4033]. J Clin Oncol 2009, 27(Suppl 1).
11. O Matzinger F Roelofsen L Mineur, et al. 2009 Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014) Eur J Cancer 45 2782 2791 10.1016/j.ejca.2009.06. 020 1:CAS:528:DC%2BD1MXhtlSqsLzF 19643599
12. M Miwa M Ura M Nishida, et al. 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274 1281 10.1016/S0959-8049(98)00058-6 1:CAS:528: DyaK1cXltlCgsrk%3D 9849491 (Pubitemid 28342121)
13. R Glynne-Jones H Meadows S Wan, et al. 2008 EXTRA-a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer Int J Radiat Oncol Biol Phys 72 119 126 1:CAS:528:DC%2BD1cXhtVamu77E 18472366
14. S Folkvord K Flatmark T Seierstad, et al. 2008 Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? Radiother Oncol 86 428 434 10.1016/j.radonc.2007.10.012 1:CAS:528:DC%2BD1cXjtlSku7g%3D 18006097 (Pubitemid 351335447)
15. N Sawada K Kondoh K Mori 2007 Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts Oncol Rep 18 775 778 1:CAS:528:DC%2BD2sXhtFygu7vL 17786335
16. C Eng GJ Chang P Das, et al. 2009 Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal [abstr 4116] J Clin Oncol 27 Suppl 15s
17. DJ Chen CS Nirodi 2007 The epidermal growth factor: a role in repair of radiation-induced DNA damage Clin Cancer Res 12 6555 6560 10.1158/1078-0432.CCR- 07-1610 (Pubitemid 350206788)
18. L Milas K Mason N Hunter, et al. 2000 In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 701 707 1:CAS:528:DC%2BD3cXhs1akt7c%3D 10690556
19. JA Bonner PM Harari J Giralt, et al. 2010 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 21 28 10.1016/S1470-2045(09)70311-0 1:CAS:528: DC%2BC3cXjslKktA%3D%3D 19897418
20. CS Karapetis S Khambata-Ford DJ Jonker, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer New Engl J Med 359 1757 1765 10.1056/NEJMoa0804385 1:CAS:528:DC%2BD1cXht12nu77J 18946061
21. MG Zampino E Magni A Sonzogni, et al. 2009 K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol 65 197 199 10.1007/s00280-009-1117-3 1:CAS:528:DC%2BD1MXhtFegu73K 19727729 There is a lack of data regarding molecular predictors of response to targeted drug therapy for anal cancer. This report is one of the first to evaluate K-ras status for this disease
22. Olivatto LO, Meton F, Bezerra M, et al.: Phase I study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC) [abstr 4609]. J Clin Oncol 2008, 26(Suppl).
23. Abrams RA, Winter KA, Regine WF, et al.: Correlation of RTOG 9704 (adjuvant therapy (rx) of pancreatic adenocarcinoma (pan ca)) radiation therapy quality assurance scores (RTQASc) with survival (S) [abstr 4523]. J Clin Oncol 2007, 25(Suppl).
24. RJ Myerson MC Garofalo I El Naqa, et al. 2009 Elective clinical target volumes for conformal therapy in anorectal cancer: a Radiation Therapy Oncology Group consensus panel contouring atlas Int J Radiat Oncol Biol Phys 74 824 830 19117696 This consensus report from the RTOG helps standardize anal cancer clinical treatment volumes
25. JK Salama L Mell DA Schomas, et al. 2007 Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience J Clin Oncol 25 4581 4586 10.1200/JCO.2007.12.0170 1:CAS:528:DC%2BD2sXht1yhsr%2FO 17925552 (Pubitemid 350035316)
26. JM Pepek CG Willett RW Clough, et al. 2009 Intensity modulated radiation therapy (IMRT) for anal cancer: The Duke University experience Int J Radiat Oncol Biol Phys 75 Suppl S267
27. L Kachnic K Winter R Myerson, et al. 2009 RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal Int J Radiat Oncol Biol Phys 75 Suppl S5 This is the first report of the RTOG clinical study evaluating the value of IMRT in reducing treatment toxicity
28. R Hoffman ML Welton B Klencke, et al. 1999 The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer Int J Radiat Oncol Biol Phys 44 127 131 10.1016/S0360-3016(98)00528-8 1:STN:280:DyaK1M3jsFaisw%3D%3D 10219805 (Pubitemid 29186199)
29. Y Seo MT Kinsella HL Reynolds, et al. 2009 Outcomes of chemoradiotherapy with 5-flurorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients Int J Radiat Oncol Biol Phys 75 143 149 1:CAS:528:DC%2BD1MXhtVegsLjM 19203845
30. EY Chiao TP Giorfano P Richardson, et al. 2008 Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era J Clin Oncol 26 474 479 10.1200/JCO.2007.14.2810 18202423 (Pubitemid 351171702)